Common use of Electronic Copy Clause in Contracts

Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives. THE BOARD OF TRUSTEES OF THE XXXXXX XXXXXXXX JUNIOR UNIVERSITY Signature: /s/ Xxxxxxx Xxxxx Name: Xxxxxxx Xxxxx Title: Acting Director, Office of Technology Licensing Date: March 24, 2015 Alexo Therapeutics International Signature: /s/ Xxxxx Xxxxxxx Name: Xxxxx Xxxxxxx Title: Chair, Board of Directors Date: March 24, 2015 *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Appendix A - Milestones [***] *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Xxxxxxxx X — Sample Reporting Form Stanford Docket No. S This report is provided pursuant to the license agreement between Stanford University and (Alexo Name) License Agreement Effective Date: Name(s) of Licensed Products being reported: Report Covering Period Yearly Maintenance Fee $ Number of Sublicenses Executed Gross Revenue U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Net Sales U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Royalty Calculation Royalty Subtotal $ Credit $ Royalty Due $ Comments: *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Appendix C — Client and Billing Agreement The Board of Trustees of the Xxxxxx Xxxxxxxx Junior University (“STANFORD”); and Alexo Therapeutics International a Cayman Islands exempted company, with a mailing address at [951 Xxxxxxx Xxxx, Xxxxx 000, Xxxxx Xxx Xxxxxxxxx, XX 00000], (“ALEXO”); have agreed to use the law firm of (“FIRM”) to prepare, file and prosecute the pending patent applications listed in Exhibit A attached hereto and maintain the patents that issue thereon (“Patents”).

Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. Portions herein identified by [*** Certain information in ***] have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this agreement document has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives. THE BOARD OF TRUSTEES OF THE XXXXXX XXXXXXXX XXXXXXXXX JUNIOR UNIVERSITY Signature: Signature /s/ Xxxxxxx Xxxxx Name: Xxxxxxx Xxxxx Title: Acting Xxxxxxxxx Xx Name Xxxxxxxxx Xx Title Director, Office of Technology Licensing Date: March Date January 24, 2015 Alexo Therapeutics International Signature: 2012 RUGA CORPORATION Signature /s/ Xxxxx Xxxxxxx Name: Xxxxx Xxxxxxx Title: Chair, Board of Directors Date: March Xxx Xxxxxxxxxx Name Xxx Xxxxxxxxxx Title President and CEO Date January 24, 2015 2012 Portions herein identified by [*** Certain information in ***] have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this agreement document has been omitted and filed separately with the Securities and Exchange Commission. APPENDIX A [*****] indicates that text has been omitted and is the subject of a confidential treatment request. Appendix A - Milestones Portions herein identified by [***] *** Certain information in ] have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this agreement document has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Xxxxxxxx X — Sample Reporting Form APPENDIXB SAMPLE REPORTING FORM Stanford Docket No. S This report is provided pursuant to the license agreement between Stanford University and (Alexo RUGA Name) License Agreement Effective Date: Name(s) of Licensed Products being reported: Product(s): Report Covering Period Yearly Maintenance Fee $ Number of Sublicenses Executed Gross Revenue U.S. Gross Revenue Non-U.S. Gross Revenue $ Sales $ Net Sales U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Royalty Calculation Royalty Subtotal $ Credit $ Royalty Due $ Comments: Portions herein identified by [*** Certain information in ***] have been omitted pursuant to a request for confidential treatment under Rule 406 of the Securities Exchange Act of 1933, as amended. A complete copy of this agreement document has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Appendix C — Client and Billing Agreement CLIENT AND BILLING AGREEMENT The Board of Trustees of the Xxxxxx Xxxxxxxx Junior University (“STANFORD”); and Alexo Therapeutics International , a Cayman Islands exempted companyCorporation of the State of, ,with a mailing address principal place of business at [951 Xxxxxxx Xxxx, Xxxxx 000, Xxxxx Xxx Xxxxxxxxx, XX 00000], (“ALEXORUGA”); have agreed to use the law firm of (“FIRM”) to prepare, file and prosecute the pending patent applications listed in Exhibit A attached hereto and maintain the patents that issue thereon (“Patents”).

Electronic Copy. The parties Parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties Parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. [Signature Page Follows] Portions of the exhibit, indicated by the xxxx “[*** Certain information in this agreement has been *],” were omitted and have been filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is Commission pursuant to the subject of a Registrant’s application requesting confidential treatment requestpursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED The parties Parties execute this Agreement in duplicate originals by their duly authorized officers or representatives. THE BOARD OF TRUSTEES OF THE XXXXXX XXXXXXXX JUNIOR UNIVERSITY Signature: /s/ PIERIS PHARMACEUTICALS, INC. Signature Name Xxxxxxx Xxxxx Name: Title President and CEO Date PIERIS PHARMACEUTICALS GMBH Signature Name Xxxxxxx Xxxxx Title: Acting DirectorTitle Managing Director Date ASKA PHARMACEUTICAL CO., Office LTD. Signature Name Xxxxxxx Xxxxxxxxx, Ph.D. Title President and Representative Director Date Portions of Technology Licensing Date: March 24the exhibit, 2015 Alexo Therapeutics International Signature: /s/ Xxxxx Xxxxxxx Name: Xxxxx Xxxxxxx Title: Chair, Board of Directors Date: March 24, 2015 indicated by the xxxx “[*** Certain information in this agreement has been *],” were omitted and have been filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED EXHIBIT A Patent Rights within the Licensed Platform IP [***] indicates that text has been omitted and is Portions of the subject of a confidential treatment request. Appendix A - Milestones exhibit, indicated by the xxxx “[***] *** Certain information in this agreement has been ],” were omitted and have been filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED EXHIBIT B Patent Rights within the Licensed Product IP [***] indicates that text has been Portions of the exhibit, indicated by the xxxx “[***],” were omitted and is the subject of a confidential treatment request. Xxxxxxxx X — Sample Reporting Form Stanford Docket No. S This report is provided pursuant to the license agreement between Stanford University and (Alexo Name) License Agreement Effective Date: Name(s) of Licensed Products being reported: Report Covering Period Yearly Maintenance Fee $ Number of Sublicenses Executed Gross Revenue U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Net Sales U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Royalty Calculation Royalty Subtotal $ Credit $ Royalty Due $ Comments: *** Certain information in this agreement has have been omitted and filed separately with the Securities and Exchange CommissionCommission pursuant to the Registrant’s application requesting confidential treatment pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED EXHIBIT C Success Criteria for Phase 2a Study [***] indicates that text has been Portions of the exhibit, indicated by the xxxx “[***],” were omitted and is have been filed separately with the subject of a Securities and Exchange Commission pursuant to the Registrant’s application requesting confidential treatment request. Appendix C — Client and Billing Agreement The Board of Trustees pursuant to Rule 24b-2 of the Xxxxxx Xxxxxxxx Junior University (“STANFORD”); Securities Exchange Act of 1934, as amended. CONFIDENTIAL TREATMENT REQUESTED EXHIBIT D The Definitive Agreements, if executed, will include the following upfront and Alexo Therapeutics International a Cayman Islands exempted companymilestone payments, with a mailing address at [951 Xxxxxxx Xxxx, Xxxxx 000, Xxxxx Xxx Xxxxxxxxx, XX 00000], (“ALEXO”); have agreed to use royalties and other terms in consideration of the law firm of (“FIRM”) to prepare, file and prosecute rights granted under the pending patent applications listed in Exhibit A attached hereto and maintain the patents that issue thereon (“Patents”).Licensed Product IP:

Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives. THE BOARD OF TRUSTEES OF THE XXXXXX XXXXXXXX JUNIOR UNIVERSITY Signature: Signature /s/ Xxxxxxx Xxxxx Name: Xxxxxxx Xxxxx Title: Xxxx Xxxxxxxxx Name Xxxx Xxxxxxxxx Title Acting Director, Office of Technology Licensing Date: March 24Director Date October 27, 2015 Alexo Therapeutics International Signature: EICCOSE, LLC. Signature /s/ Xxxxx Xxxxxxx Name: Xxxx Name Xxxxx Xxxxxxx Title: Chair, Board of Directors Date: March 24, 2015 **Xxxx Title President and CEO Date [ * ] = Certain confidential information contained in this agreement has been omitted and document, marked by brackets, is filed separately with the Securities and Exchange CommissionCommission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. [***APPENDIX A EICCOSE DEVELOPMENT AND REGULATORY PLAN FOR LTB4 INHIBITORS IN LYMPHEDEMA [ * ] indicates that text has been omitted and is the subject of a [ * ] = Certain confidential treatment request. Appendix A - Milestones [***] *** Certain information contained in this agreement has been omitted and document, marked by brackets, is filed separately with the Securities and Exchange CommissionCommission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Xxxxxxxx XXXXXXXX X — – Sample Reporting Form Stanford Docket NoSTANFORD DOCKET NO. S This report is provided pursuant to the license agreement between Stanford University and S14-323 THIS REPORT IS PROVIDED PURSUANT TO THE LICENSE AGREEMENT BETWEEN STANFORD UNIVERSITY AND (Alexo NameEICCOSE, LLC) License Agreement Effective DateLICENSE AGREEMENT EFFECTIVE DATE: Name(s) of Licensed Products being reported: Report Covering Period Yearly Maintenance Fee REPORT COVERING PERIOD YEARLY MAINTENANCE FEE $ Number of Sublicenses Executed Gross Revenue U.S. Gross Revenue Non-U.S. Gross Revenue NUMBER OF SUBLICENSES EXECUTED NET SALES $ ROYALTY CALCULATION ROYALTY SUBTOTAL $ Net Sales U.S. Gross Revenue Non-U.S. Gross Revenue CREDIT $ ROYALTY DUE $ Royalty Calculation Royalty Subtotal $ Credit $ Royalty Due $ CommentsCOMMENTS: **[ * ] = Certain confidential information contained in this agreement has been omitted and document, marked by brackets, is filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Appendix C — Client and Billing Agreement The Board of Trustees Commission pursuant to Rule 24b-2 of the Xxxxxx Xxxxxxxx Junior University (“STANFORD”); and Alexo Therapeutics International a Cayman Islands exempted companySecurities Exchange Act of 1934, with a mailing address at [951 Xxxxxxx Xxxx, Xxxxx 000, Xxxxx Xxx Xxxxxxxxx, XX 00000], (“ALEXO”); have agreed to use the law firm of (“FIRM”) to prepare, file and prosecute the pending patent applications listed in Exhibit A attached hereto and maintain the patents that issue thereon (“Patents”)as amended.

Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***] indicates that text has been omitted and is the subject of a confidential treatment request], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives. THE BOARD OF TRUSTEES OF THE XXXXXX XXXXXXXX JUNIOR UNIVERSITY SignatureBy: /s/ Xxxxxxx Xxxxx Xxxxxxxxx Xx Name: Xxxxxxx Xxxxx Xxxxxxxxx Xx Title: Acting Executive Director, Office of Technology Licensing Date: March 24June 1, 2015 Alexo Therapeutics International SignatureBOLT THERAPEUTICS By: /s/ Xxxxx Xxxxxxx Xxxx-Xxxx Xx Name: Xxxxx Xxxxxxx Xxxx-Xxxx Xx Title: Chair, Board of Directors President Date: March 24June 1, 2015 *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***] indicates that text has been omitted and is the subject of a confidential treatment request], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. Appendix A - Milestones [***] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [*** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission*], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. Appendix B — Sample Reporting Form [***] indicates that text has been omitted and is the subject of a confidential treatment request. Xxxxxxxx X — Sample Reporting Form Stanford Docket No. S This report is provided pursuant to the license agreement between Stanford University and (Alexo Name) License Agreement Effective Date: Name(s) of Licensed Products being reported: Report Covering Period Yearly Maintenance Fee $ Number of Sublicenses Executed Gross Revenue U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Net Sales U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Royalty Calculation Royalty Subtotal $ Credit $ Royalty Due $ Comments: CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [*** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission*], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. Appendix C — [***] indicates that text has been omitted and is the subject of a confidential treatment request[***] CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENTS, MARKED BY [***], HAS BEEN OMITTED BECAUSE BOLT BIOTHERAPEUTICS, INC. HAS DETERMINED THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD LIKELY CAUSE COMPETITIVE HARM TO BOLT BIOTHERAPEUTICS, INC. IF PUBLICLY DISCLOSED. Appendix C D — Client and Billing Agreement The Board of Trustees of the Xxxxxx Xxxxxxxx Junior University (“STANFORD”); and Alexo Therapeutics International a Cayman Islands exempted company, with a mailing address at [951 Xxxxxxx Xxxx, Xxxxx 000, Xxxxx Xxx Xxxxxxxxx, XX 00000], (“ALEXO”); have agreed to use the law firm of (“FIRM”) to prepare, file and prosecute the pending patent applications listed in Exhibit A attached hereto and maintain the patents that issue thereon (“Patents”).Equity Purchase Rights

Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. *** Certain information in this agreement has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is the subject of a confidential treatment request. The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives. THE BOARD OF TRUSTEES OF THE XXXXXX XXXXXXXX JUNIOR UNIVERSITY Signature: /s/ Xxxxxxx Xxxxx Xxxxxxxxx Xx Name: Xxxxxxx Xxxxx Xxxxxxxxx Xx Title: Acting Director, Office of Technology Licensing Executive Director Date: March 24November 19, 2015 Alexo Therapeutics International Signature: FORTY SEVEN, INC. Signature /s/ Xxxxx Xxxxxxx Xxxxxxxx XxxXxxxxx Name: Xxxxx Xxxxxxx Xxxxxxxx XxxXxxxxx Title: Chair, Board of Directors CEO Date: March 24November 19, 2015 [*** ] = Certain confidential information contained in this agreement document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is Commission pursuant to Rule 406 of the subject Securities Act of a confidential treatment request1933, as amended. Appendix A - Milestones [**] [*] *** = Certain confidential information contained in this agreement document, marked by brackets, has been omitted and filed separately with the Securities and Exchange CommissionCommission pursuant to Rule 406 of the Securities Act of 1933, as amended. [***] indicates that text has been omitted and is the subject of a confidential treatment request. Xxxxxxxx X — Appendix B – Sample Reporting Form Stanford Docket No. S S- This report is provided pursuant to the license agreement between Stanford University and (Alexo Company Name) License Agreement Effective Date: Name(s) of Licensed Products being reported: Report Covering Period Yearly Maintenance Fee $ Number of Sublicenses Executed Gross Revenue U.S. Gross Revenue Non-U.S. Gross Revenue $ $ Net Sales U.S. Gross Revenue Net Sales Non-U.S. Gross Revenue Net Sales $ $ Royalty Calculation Royalty Subtotal $ Credit $ Royalty Due $ Comments: [*** ] = Certain confidential information contained in this agreement document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission. [***] indicates that text has been omitted and is Commission pursuant to Rule 406 of the subject Securities Act of a confidential treatment request1933, as amended. Appendix C — – Client and Billing Agreement The Board of Trustees of the Xxxxxx Xxxxxxxx Junior University (“STANFORD”); and Alexo Therapeutics International a Cayman Islands exempted companyCorporation of the State of , with a mailing address principal place of business at [951 Xxxxxxx Xxxx, Xxxxx 000, Xxxxx Xxx Xxxxxxxxx, XX 00000], (“ALEXOCOMPANY”); have agreed to use the law firm of (“FIRM”) to prepare, file and prosecute the pending patent applications listed in Exhibit A attached hereto and maintain the patents that issue thereon (“Patents”).